Abstract
Mutant forms of the c-ABL gene are well known to be involved in hematopoietic malignancies such as chronic myeloid leukemia (CML). CML patients possess a fused BCR-ABL gene that activates the Abl tyrosine kinase domain within Bcr-Abl. In general fusion proteins that cause oligomerization of Abl lead to activation of its tyrosine kinase activity. In this review, we highlight recent discoveries indicating that the activated c-Abl tyrosine kinase, not as a fusion protein, plays an important role in malignant solid tumors of lung and breast.
Original language | English (US) |
---|---|
Pages (from-to) | 4385-4391 |
Number of pages | 7 |
Journal | Oncogene |
Volume | 27 |
Issue number | 32 |
DOIs | |
State | Published - Jul 24 2008 |
Keywords
- Breast cancer
- FUS1
- Imatinib
- Lung cancer
- NSCLC
- c-Abl
ASJC Scopus subject areas
- Molecular Biology
- Genetics
- Cancer Research